All In Biotech

NDA 219920 · Avyxa Holdings

Avgemsi

Gemcitabine Hydrochloride · Intravenous

Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Jun 27, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3,514

702 Phase 3, 512 recruiting

FAERS reports

40,140

38,987 serious, 7,548 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 27, 2026.

AVGEMSI is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin, for the treatment of non-small cell lung cancer. ( 1.3 ) as a single agent for the treatment of pancreatic cancer. ( 1.4 ) 1.1 Ovarian Cancer AVGEMSI in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer AVGEMSI in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer AVGEMSI in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer AVGEMSI is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. AVGEMSI is indicated for patients previously treated with fluorouracil.

Mechanism: Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary. Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabine diphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleoside triphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabine triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 27, 2025 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetter
3 products under this application
  • AVGEMSI · GEMCITABINE HYDROCHLORIDE EQ 2GM BASE/52.6ML (EQ 38MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • AVGEMSI · GEMCITABINE HYDROCHLORIDE EQ 200MG BASE/5.26ML (EQ 38MG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • AVGEMSI · GEMCITABINE HYDROCHLORIDE EQ 1GM BASE/26.3ML (EQ 38MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Gemcitabine" as an intervention, any sponsor and status, largest first.

All 3,514 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • disease progression4,646
  • thrombocytopenia3,043
  • off label use2,910
  • drug ineffective2,705
  • neutropenia2,703
  • anaemia2,483
  • malignant neoplasm progression2,153
  • nausea2,032
  • pyrexia1,978
  • fatigue1,707
  • diarrhoea1,674
  • vomiting1,616

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004486
2005473
2006521
2007344
2008418
2009591
2010452
2011571
2012885
2013800
20141,061
20151,994
20162,392
20172,252
20182,507
20192,656
20202,546
20212,586
20223,132
20234,004
20243,373
20253,434
20262,662

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,445 on PubMed

Sponsor: Avyxa Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.